Brief: Daré Bioscience Announces Upcoming Webinar To Review Additional Data From Exploratory Phase 2b Respond Study Of Sildenafil Cream, 3.6% In Women With Female Sexual Arousal Disorder
06/07/2023 14:33
July 6 (Reuters) - Dare Bioscience Inc DARE.O :
* DARÉ BIOSCIENCE ANNOUNCES UPCOMING WEBINAR TO REVIEW
ADDITIONAL
DATA FROM EXPLORATORY PHASE 2B RESPOND STUDY OF SILDENAFIL
CREAM, 3.6% IN WOMEN WITH FEMALE SEXUAL AROUSAL DISORDER
Source text for Eikon: ID:nGNX4fhSLC
Further company coverage: DARE.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Dare Bioscience
See all newsBrief: Dare Bioscience - Files For Resale Of Up To 8,934,345 Shares Of Common Stock - SEC Filing
Brief: Daré Bioscience CEO Sabrina Martucci Johnson Named To Forbes 2026 “50 Over 50 Innovation” List
NASDAQ RESUMED AT 12:50 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:45 PM
Dare Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary